23 companies · FY2026 results (earnings releases, consolidated)
Chugai ranks first for operating profit in the Pharmaceutical industry at ¥598.8B. The top three are Chugai (¥598.8B), Otsuka (¥479.4B) and Takeda (¥408.8B).
Across the 23 companies the average is ¥119.8B and the median ¥36.4B. Nxera comes last at ¥-8.5B.
6 of 23 companies are above the average.
4 companies posted an operating loss: Kaken, Kissei, Peptide Dream, Nxera.
Shares 1Y is a closing-price reference (vs. about a year earlier). YoY compares with the previous full-year results.
| Rank | Company | Operating profit | Average salary | Revenue | Operating margin |
|---|---|---|---|---|---|
| 1 | Chugai4519 | ¥598.8B | ¥12.1M | ¥1.3T | 47.6% |
| 2 | Otsuka4578 | ¥479.4B | ¥10.6M | ¥2.5T | 19.4% |
| 3 | Takeda4502 | ¥408.8B | ¥11.0M | ¥4.5T | 9.1% |
| 4 | Astellas4503 | ¥382.6B | ¥10.5M | ¥2.1T | 17.9% |
| 5 | Daiichi Sankyo4568 | ¥229.1B | ¥11.0M | ¥2.1T | 10.8% |
| 6 | Shionogi4507 | ¥166.7B | ¥10.0M | ¥499.7B | 33.4% |
| 7 | Sumitomo Pharma4506 | ¥107.3B | ¥9.06M | ¥453.3B | 23.7% |
| 8 | Ono4528 | ¥92.2B | ¥10.2M | ¥515.8B | 17.9% |
| 9 | Santen4536 | ¥47.8B | ¥9.02M | ¥291.6B | 16.4% |
| 10 | Eisai4523 | ¥44.1B | ¥11.2M | ¥825.4B | 5.3% |
| 11 | Rohto4527 | ¥41.1B | ¥8.26M | ¥343.7B | 12.0% |
| 12 | Suzuken9987 | ¥36.4B | ¥7.45M | ¥2.5T | 1.5% |
| 13 | Nippon Shinyaku4516 | ¥35.5B | ¥9.19M | ¥170.8B | 20.8% |
| 14 | Tsumura4540 | ¥35.2B | ¥9.11M | ¥192.6B | 18.3% |
| 15 | Towa4553 | ¥23.1B | ¥6.95M | ¥273.7B | 8.4% |
| 16 | Sawai4887 | ¥15.9B | ¥9.38M | ¥201.7B | 7.9% |
| 17 | Kobayashi4967 | ¥14.9B | ¥7.57M | ¥165.7B | 9.0% |
| 18 | Zeria4559 | ¥12.4B | ¥7.99M | ¥89.2B | 13.9% |
| 19 | JCR4552 | ¥555M | ¥8.19M | ¥40.3B | 1.4% |
| 20 | Kaken4521 | ¥-899M | ¥8.75M | ¥76.9B | -1.2% |
| 21 | Kissei4547 | ¥-2.9B | ¥7.98M | ¥97.4B | -3.0% |
| 22 | Peptide Dream4587 | ¥-5.0B | ¥11.7M | ¥18.5B | -27.1% |
| 23 | Nxera4565 | ¥-8.5B | ¥12.6M | ¥29.6B | -28.6% |
Revenue and operating profit are from the latest full-year consolidated results. Average salary is for the reporting entity per its annual securities report; pure holding companies with fewer than 50 staff are excluded.
